Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlioVax: DC Vaccination in Glioblastoma
NCT03395587Phase 2Active, not recruiting
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Mar 2018
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) (2 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Overall Survival up to 34 months. Started Mar 2018; status: active, not recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03395587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395587.